What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

RNA Modification: Types, Steps, and Why It Matters

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

What Is RNA Modification?

RNA modification refers to the collection of chemical and enzymatic changes that occur to RNA molecules after they are synthesized from DNA during transcription. These post-transcriptional alterations do not change the nucleotide sequence encoded in the DNA template; instead, they change the RNA molecule itself—its structure, stability, coding capacity, or interactions with other molecules.

The central dogma of molecular biology describes information flow from DNA to RNA to protein. For decades, RNA was viewed as a passive intermediary that simply carried genetic instructions from the nucleus to the ribosome. That view is outdated. In reality, the RNA transcript produced by RNA polymerase is a primary transcript, or pre-mRNA, that must undergo extensive processing before it can function. Even after maturation, RNA molecules continue to receive chemical marks that fine-tune their behavior.

RNA modification is fundamentally different from DNA mutation. A mutation is a permanent change in the genetic blueprint that is inherited through replication. RNA modification, by contrast, is a regulated, often reversible process that occurs on individual RNA molecules without altering the underlying DNA sequence. This distinction matters because RNA modifications allow a single gene to produce multiple functional products, enable rapid cellular responses to environmental signals, and provide an additional layer of gene regulation that operates after transcription has already occurred.

The study of RNA modification has exploded in recent decades. More than 170 distinct chemical modifications have been identified across all types of RNA, from messenger RNA (mRNA) to transfer RNA (tRNA), ribosomal RNA (rRNA), and various non-coding RNAs. These modifications are not random decorations; they are installed by specific enzymes, recognized by specific reader proteins, and removed by specific eraser proteins. The dynamic interplay of these factors determines the fate of every RNA molecule in the cell.

Types of RNA Modification

RNA modification encompasses several mechanistically distinct processes. Some modifications alter the nucleotide sequence itself through editing. Others remove large segments of the transcript through splicing. Still others add chemical groups to the ends of the molecule or to individual bases. Each type serves different purposes and is carried out by different molecular machinery.

RNA Editing

RNA editing is the process by which the nucleotide sequence of an RNA molecule is altered after transcription. Unlike splicing, which removes introns, RNA editing changes individual bases within the RNA sequence. The two most common forms are adenosine-to-inosine (A-to-I) editing and cytidine-to-uridine (C-to-U) editing.

A-to-I editing is catalyzed by the ADAR (adenosine deaminase acting on RNA) family of enzymes. ADAR enzymes recognize double-stranded RNA regions and deaminate adenosine residues, converting them to inosine. Because inosine base-pairs with cytidine rather than adenosine, the translational machinery reads inosine as guanosine. This means that A-to-I editing effectively changes an A to a G in the coding sequence, which can alter the amino acid specified by a codon.

C-to-U editing is catalyzed by the APOBEC (apolipoprotein B mRNA editing catalytic polypeptide) family of enzymes. The classic example is apolipoprotein B (APOB) mRNA, where C-to-U editing creates a premature stop codon. This produces a truncated protein in the intestine while the full-length protein is produced in the liver from the unedited mRNA.

RNA editing is not limited to protein-coding sequences. Editing can also occur in untranslated regions, introns, and non-coding RNAs, where it can affect splicing patterns, microRNA targeting, or RNA stability.

RNA Splicing

RNA splicing is the process by which introns—non-coding sequences that interrupt genes—are removed from the pre-mRNA, and exons—coding sequences—are joined together. This reaction is catalyzed by the spliceosome, a large ribonucleoprotein complex composed of five small nuclear RNAs (snRNAs) and more than 100 proteins.

The spliceosome recognizes specific sequences at the intron boundaries: the 5' splice site, the 3' splice site, and the branch point. The splicing reaction proceeds through two transesterification reactions. In the first, the 2'-hydroxyl of the branch point adenosine attacks the 5' splice site, releasing the 5' exon and forming a lariat structure. In the second, the 3'-hydroxyl of the 5' exon attacks the 3' splice site, joining the exons and releasing the intron lariat.

Alternative splicing is a variation on this theme in which different combinations of exons are joined together, producing multiple mRNA isoforms from a single gene. This process is regulated by splicing factors that bind to enhancer or silencer sequences in the pre-mRNA and either promote or repress the use of particular splice sites. It is estimated that more than 95% of human multi-exon genes undergo alternative splicing, making it a major source of protein diversity.

5' Capping and 3' Polyadenylation

The 5' cap is a modified guanosine nucleotide added to the 5' end of eukaryotic mRNAs. The capping reaction occurs co-transcriptionally, when the nascent RNA is only 20–30 nucleotides long. A phosphatase removes the terminal phosphate, a guanylyltransferase adds a guanosine monophosphate in a 5'-to-5' linkage, and a methyltransferase adds a methyl group to the N7 position of the guanine, producing the cap 0 structure (m7G). In higher eukaryotes, additional methylations on the first two nucleotides produce cap 1 and cap 2 structures.

The 5' cap serves multiple functions. It protects the mRNA from 5'-to-3' exonucleases, promotes translation by recruiting the cap-binding complex eIF4F, and is required for efficient splicing and polyadenylation. The cap also marks the mRNA as "self" to the innate immune system, preventing inappropriate activation of antiviral responses.

3' polyadenylation involves the addition of a poly(A) tail—a stretch of 50–250 adenosine residues—to the 3' end of most eukaryotic mRNAs. The process begins with cleavage of the pre-mRNA at a site downstream of the conserved AAUAAA polyadenylation signal. The cleavage and polyadenylation specificity factor (CPSF) and cleavage stimulation factor (CstF) recognize this signal and recruit the cleavage factors and poly(A) polymerase. After cleavage, poly(A) polymerase adds adenosines, and the poly(A)-binding protein (PABP) coats the tail.

The poly(A) tail protects the mRNA from 3'-to-5' degradation, facilitates translation, and plays a role in transcription termination. The length of the poly(A) tail can be dynamically regulated, with deadenylation serving as a key step in mRNA decay.

Chemical Modifications

Beyond editing, capping, and polyadenylation, RNA molecules carry numerous chemical modifications on individual nucleotides. These modifications are installed post-transcriptionally by specific enzymes and can be removed by others, making them dynamic regulators of RNA function.

The most abundant internal modification in mRNA is N6-methyladenosine (m6A). This modification is installed by the METTL3-METTL14 methyltransferase complex, removed by the demethylases FTO and ALKBH5, and recognized by reader proteins such as YTHDF2. m6A affects nearly every aspect of mRNA metabolism, including splicing, export, translation, and degradation.

Other common modifications include N1-methyladenosine (m1A), 5-methylcytosine (m5C), pseudouridine (Ψ), and 2'-O-methylation. Pseudouridine, the isomerization of uridine, is particularly abundant in rRNA and tRNA, where it stabilizes RNA structure. Transfer RNA contains the highest density and diversity of modifications, with more than 90 distinct modifications identified across all organisms. These modifications are essential for tRNA stability, codon-anticodon recognition, and accurate translation. For a deeper look at the specific modifications found on transfer RNAs, see tRNA Modification.

Steps of RNA Modification

While the specific steps vary depending on the type of modification, the general sequence of events in eukaryotic gene expression follows a predictable order. Understanding this order clarifies how a single gene produces a functional RNA.

Transcription initiation and elongation. RNA polymerase II (Pol II) begins synthesizing pre-mRNA from the DNA template. The C-terminal domain (CTD) of Pol II is phosphorylated at specific serine residues, creating a platform for recruiting RNA processing factors.

Co-transcriptional 5' capping. When the nascent RNA reaches approximately 20–30 nucleotides in length, the capping enzymes associate with the phosphorylated CTD and add the 7-methylguanosine cap to the 5' end. This occurs before the transcript is long enough to be released from the polymerase.

Splicing of introns. As transcription continues, the spliceosome assembles on the pre-mRNA and removes introns. Splicing is largely co-transcriptional, meaning that introns are often removed while the RNA is still being synthesized. The order of intron removal is not necessarily 5'-to-3'; it depends on the specific gene and the splicing factors present.

3' cleavage and polyadenylation. When Pol II transcribes past the polyadenylation signal, the CPSF and CstF complexes recognize the AAUAAA sequence and the downstream GU-rich element. The RNA is cleaved at a site 10–30 nucleotides downstream of the signal, and poly(A) polymerase adds the poly(A) tail. This cleavage event triggers transcription termination.

RNA editing and chemical modification. Some modifications, such as A-to-I editing, can occur co-transcriptionally. Others, particularly chemical modifications like m6A, are installed after splicing and polyadenylation are complete. The timing of these modifications is regulated and can vary between transcripts.

Nuclear export. The mature mRNA, now capped, spliced, polyadenylated, and modified, is exported through the nuclear pore complex to the cytoplasm. Export factors recognize the processed mRNA and distinguish it from unprocessed or aberrant transcripts.

Cytoplasmic regulation and translation. In the cytoplasm, the mRNA may undergo additional modifications, be localized to specific cellular compartments, be translated by ribosomes, or be degraded. The modifications installed earlier in the process influence all of these fates.

This sequence is not rigid. Some modifications, such as m6A, can be installed co-transcriptionally on the nascent RNA. Others, such as certain tRNA modifications, occur after the RNA has been fully processed and exported. The key point is that RNA modification is an integral part of gene expression, not an optional add-on.

Examples of RNA Modification

Concrete examples illustrate the diversity and functional importance of RNA modification.

Alternative splicing in humans. The DSCAM (Down syndrome cell adhesion molecule) gene in Drosophila can theoretically produce over 38,000 distinct mRNA isoforms through alternative splicing. In humans, the TNNT2 (cardiac troponin T) gene produces different isoforms in cardiac muscle versus skeletal muscle through tissue-specific alternative splicing. The MECP2 gene, which is mutated in Rett syndrome, undergoes extensive alternative splicing that produces multiple isoforms with different functions. These examples demonstrate how a single gene can generate multiple proteins with distinct properties.

A-to-I RNA editing in the brain. The GRIA2 (glutamate receptor ionotropic AMPA2) gene encodes a subunit of the AMPA glutamate receptor. A-to-I editing at the Q/R site in the mRNA changes a glutamine codon (CAG) to an arginine codon (CGG). This single amino acid change dramatically alters the calcium permeability of the receptor. Unedited GRIA2 mRNA produces receptors that are highly permeable to calcium, which can cause neuronal toxicity. More than 99% of GRIA2 mRNA in adult human brains is edited at this site. Editing is also critical for the GRIN genes encoding NMDA receptors, where A-to-I editing affects receptor trafficking and function. For a broader view of how these regulatory layers interact with chromatin structure, see Chromatin Modification.

tRNA modifications. Transfer RNAs contain the highest density of chemical modifications of any RNA species. For example, the modification m1A37 (1-methyladenosine at position 37) is found in many tRNAs and is required for accurate codon recognition. The modification t6A (threonylcarbamoyladenosine) at position 37 is essential for the decoding of ANN codons. In humans, mutations in genes encoding tRNA modification enzymes cause various diseases. For instance, mutations in ELP1 (elongator complex protein 1), which is required for a specific modification at the wobble position of certain tRNAs, cause familial dysautonomia, a neurodegenerative disease. The modification mcm5s2U (5-methoxycarbonylmethyl-2-thiouridine) at the wobble position of tRNA Lys(UUU) is required for accurate decoding of AAA and AAG codons; its absence causes mitochondrial dysfunction.

m6A modification in mRNA. The m6A modification is installed on thousands of human mRNAs. The reader protein YTHDF2 promotes degradation of m6A-modified mRNAs, while YTHDF1 promotes their translation. In embryonic stem cells, m6A is required for proper differentiation. Depletion of METTL3, the catalytic subunit of the m6A methyltransferase, causes defects in stem cell maintenance and differentiation. In cancer, dysregulation of m6A has been linked to tumor progression. For example, METTL3 is overexpressed in acute myeloid leukemia, where it promotes leukemogenesis by modifying mRNAs encoding key oncogenes.

Why RNA Modification Matters

RNA modification is not a minor detail of molecular biology; it is a fundamental mechanism that expands the functional capacity of the genome and enables precise regulation of gene expression.

Increasing protein diversity. The human genome contains approximately 20,000 protein-coding genes, yet the human proteome is estimated to contain over 100,000 distinct protein species. Alternative splicing is the primary mechanism for this expansion, allowing a single gene to produce multiple protein isoforms with different functions, localizations, or activities. RNA editing adds another layer, changing amino acid sequences in a regulated manner.

Regulating gene expression. RNA modifications control the abundance and translation of mRNAs. The m6A modification can promote or repress translation depending on the reader protein that binds it. The poly(A) tail length influences mRNA stability and translation efficiency. The 5' cap is required for efficient translation. These modifications allow cells to rapidly adjust protein production in response to signals without changing transcription rates.

Enabling tissue-specific functions. Many RNA modifications are tissue-specific or developmentally regulated. A-to-I editing is particularly prevalent in the brain, where it fine-tunes neurotransmitter receptor properties. Alternative splicing differs between tissues, producing muscle-specific or neuron-specific isoforms. This tissue specificity allows the same gene to serve different functions in different cell types.

Maintaining cellular homeostasis. RNA modifications are essential for basic cellular processes. tRNA modifications ensure accurate and efficient translation. rRNA modifications are required for ribosome assembly and function. Splicing defects cause the production of aberrant proteins that are often toxic. Cells have quality control mechanisms, such as nonsense-mediated decay, that detect and degrade mRNAs with premature stop codons, many of which arise from splicing errors.

Contributing to disease. Mutations in genes encoding RNA modification enzymes cause numerous human diseases. Mutations in SMN1 (survival motor neuron 1), which is required for snRNP assembly and splicing, cause spinal muscular atrophy. Mutations in FMR1 (fragile X messenger ribonucleoprotein 1), which regulates translation of specific mRNAs, cause fragile X syndrome. Dysregulation of RNA editing has been linked to amyotrophic lateral sclerosis, depression, and cancer. The importance of RNA modification in disease has made it an attractive target for therapeutic intervention.

Interacting with other regulatory layers. RNA modification does not operate in isolation. It is coordinated with Histone Modification and Epigenetic Modification to control gene expression. Histone modifications influence transcription initiation and elongation, which in turn affects co-transcriptional RNA processing. The Transcription Factor network that controls gene expression also regulates the expression of RNA modification enzymes, creating a feedback loop. This integration ensures that RNA processing is coordinated with the transcriptional state of the cell.

How Scientists Study RNA Modification

Studying RNA modification requires methods to detect, quantify, and manipulate specific modifications. The field has advanced rapidly with the development of high-throughput sequencing and genome editing technologies.

RNA sequencing (RNA-seq). Standard RNA-seq measures transcript abundance and can identify alternative splicing events by analyzing exon-junction reads. However, standard RNA-seq does not detect most chemical modifications because they do not cause sequence changes during reverse transcription. Specialized approaches are needed.

Antibody-based enrichment for m6A. The most widely used method for studying m6A is m6A-seq (also called MeRIP-seq). In this approach, total RNA is fragmented to approximately 100 nucleotides, and an antibody specific for m6A is used to immunoprecipitate m6A-containing fragments. The enriched fragments are then sequenced, and peaks are identified by comparing the immunoprecipitated sample to an input control. This method identifies m6A sites at a resolution of approximately 100–200 nucleotides. A higher-resolution variant, miCLIP (m6A individual-nucleotide-resolution cross-linking and immunoprecipitation), uses UV cross-linking to identify m6A sites at single-nucleotide resolution.

Bisulfite sequencing for m5C. 5-methylcytosine in RNA can be detected by bisulfite conversion, in which unmethylated cytosines are converted to uracil while methylated cytosines are resistant. After bisulfite treatment, the RNA is reverse transcribed, PCR-amplified, and sequenced. Sites that remain as cytosine are inferred to be methylated. This method is analogous to bisulfite sequencing for DNA methylation.

Direct RNA sequencing. Nanopore sequencing can detect RNA modifications directly. As an RNA molecule passes through a nanopore, the current changes depend on the nucleotide identity and its modifications. Modified nucleotides produce characteristic current signatures that can be distinguished from unmodified nucleotides. This method is still being optimized but has the advantage of detecting multiple modifications simultaneously without antibody enrichment.

CRISPR-based screens. CRISPR-Cas9 genome editing has been used to knock out genes encoding RNA modification enzymes and identify their targets. In a typical screen, a library of guide RNAs targeting all known writers, readers, and erasers is introduced into cells. The cells are then subjected to a selection, and the guide RNAs that are enriched or depleted identify genes that are important for the phenotype. This approach has identified new components of the m6A pathway and revealed functional connections between RNA modification and other cellular processes.

Mass spectrometry. Mass spectrometry can identify and quantify RNA modifications with high precision. RNA is digested to individual nucleosides, which are separated by liquid chromatography and analyzed by mass spectrometry. This approach can detect known modifications and discover new ones, but it requires relatively large amounts of RNA and does not provide positional information.

Common Misconceptions and Pitfalls

Several misconceptions about RNA modification are common among students encountering the topic for the first time.

Misconception 1: RNA modification is the same as DNA mutation. This is incorrect. DNA mutations are permanent changes in the genetic material that are inherited through cell division. RNA modifications are changes to RNA molecules that do not alter the DNA sequence. They are often reversible and occur on individual RNA molecules, not on the genome. The distinction is fundamental: mutations change the blueprint; modifications change the product.

Misconception 2: All RNA is modified. In reality, the extent of modification varies greatly. Some RNAs, such as tRNAs and rRNAs, are heavily modified. Others, such as many long non-coding RNAs, may carry few or no modifications. Even within a single mRNA, only a subset of nucleotides is modified. The presence and location of modifications are highly regulated and context-dependent.

Misconception 3: RNA modifications are static. Many modifications are dynamic. The m6A modification is installed by writers, removed by erasers, and recognized by readers. The levels of m6A on a given mRNA can change rapidly in response to cellular signals. Poly(A) tail length is also dynamic, with deadenylation enzymes shortening the tail over time. This dynamism allows cells to fine-tune gene expression.

Misconception 4: Splicing always produces the same result. Alternative splicing means that the same pre-mRNA can be processed in multiple ways. The choice of splice sites is regulated by splicing factors whose expression and activity vary between cell types and in response to signals. This is not an error; it is a regulated process that generates diversity.

Misconception 5: RNA editing is rare. While RNA editing is less common than splicing, it is not rare. A-to-I editing occurs at millions of sites in the human transcriptome, primarily in Alu elements in introns and untranslated regions. The editing of protein-coding sites is less common but can have profound functional consequences.

Pitfall 1: Confusing co-transcriptional and post-transcriptional processes. Many RNA modifications occur co-transcriptionally, meaning they happen while the RNA is still being synthesized. The 5' cap is added when the transcript is only 20–30 nucleotides long. Splicing often occurs before transcription is complete. The term "post-transcriptional" is used broadly to describe all processing that occurs after the nucleotide is incorporated into the RNA, but it does not mean that all processing waits until transcription is finished.

Pitfall 2: Assuming that one modification has one effect. The same modification can have different effects depending on its location and context. m6A in the 5' untranslated region can promote translation, while m6A in the coding sequence can inhibit translation. m6A in the 3' untranslated region can promote mRNA degradation. The effect depends on which reader proteins bind and where.

Pitfall 3: Overlooking the role of RNA modification in non-coding RNAs. RNA modification is not limited to mRNA. Transfer RNA, ribosomal RNA, small nuclear RNA, microRNA, and long non-coding RNA all carry modifications that affect their function. For example, modifications in microRNA precursors can affect microRNA processing and target selection.

Frequently Asked Questions

What is RNA modification?

RNA modification is any post-transcriptional change to an RNA molecule that alters its structure, sequence, or chemical properties. This includes RNA editing (base changes), splicing (intron removal), 5' capping, 3' polyadenylation, and chemical modifications such as methylation. These changes occur after transcription and affect the function, stability, or localization of the RNA.

What are the steps of RNA modification?

The general sequence is: transcription produces pre-mRNA; the 5' cap is added co-transcriptionally; introns are removed by splicing; the 3' end is cleaved and polyadenylated; RNA editing and chemical modifications may occur; and the mature RNA is exported to the cytoplasm. The exact order and timing vary depending on the modification and the transcript.

What are the types of RNA modification?

The major types are RNA editing (A-to-I and C-to-U base changes), RNA splicing (intron removal, including alternative splicing), 5' capping, 3' polyadenylation, and chemical modifications (m6A, m5C, pseudouridine, 2'-O-methylation, and many others). Transfer RNA carries the greatest diversity of chemical modifications.

Can you give examples of RNA modification?

Examples include A-to-I editing of GRIA2 mRNA in the brain, which changes calcium permeability of AMPA receptors; alternative splicing of TNNT2 in muscle; m6A modification of mRNAs in embryonic stem cells, which is required for differentiation; and tRNA modifications such as m1A37 and t6A, which are essential for accurate translation.

Why is RNA modification important?

RNA modification increases protein diversity, regulates gene expression, enables tissue-specific functions, maintains cellular homeostasis, and contributes to disease when dysregulated. It allows a single gene to produce multiple products and enables rapid, reversible regulation of gene expression.

How does RNA modification differ from DNA mutation?

A DNA mutation is a permanent change in the genetic sequence that is inherited through replication. RNA modification is a change to an RNA molecule that does not alter the DNA sequence. RNA modifications are often reversible, occur on individual RNA molecules, and are regulated by specific enzymes. Mutations change the blueprint; modifications change the product.

Key Takeaways

RNA modification encompasses RNA editing, splicing, 5' capping, 3' polyadenylation, and chemical modifications that occur after transcription.
These processes are carried out by specific enzymes and are highly regulated, not random events.
Alternative splicing and RNA editing allow a single gene to produce multiple protein isoforms, greatly expanding the functional capacity of the genome.
Chemical modifications such as m6A are dynamic—installed by writers, removed by erasers, and read by reader proteins—and regulate mRNA stability, translation, and localization.
RNA modification is essential for normal cell function; defects in RNA modification enzymes cause numerous human diseases, including neurodegeneration and cancer.
RNA modification is distinct from DNA mutation: it does not alter the genetic blueprint and is often reversible.
Advanced methods including m6A-seq, bisulfite sequencing, nanopore direct RNA sequencing, and CRISPR-based screens are used to study RNA modifications and their functions.